# Escalier Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/escalier-biosciences-b-v

- Industry: Pharmaceuticals
- Headquarters: Nijmegen, Netherlands
- Website: www.escalierbio.com
- Total disclosed funding: $19M
- Latest round: Series B (Mar 13, 2018)
- Investors on record: 3

## About

Based in Nijmegen, Netherlands, Escalier Biosciences B.V. is a biotechnology company focused on developing innovative solutions in the life sciences sector, addressing critical health challenges through advanced research and technology.Escalier Biosciences B.V. specializes in biotechnology, aiming to provide innovative solutions in the life sciences field. The company is based in Nijmegen, Netherlands. It has successfully raised USD 19.00 mn in its LATEST ROUND, a Series B funding led by Forbion, alongside investors BioGeneration Ventures and New Science Ventures. The firm has completed a total of 3 deals. The details about the founder and CEO of Escalier Biosciences B.V. have not been provided.Escalier Biosciences B.V. focuses on the development of cutting-edge biotechnological products aimed at addressing significant health issues. Their work includes research and development in areas such as drug discovery and diagnostics, leveraging advanced methodologies to create effective health solutions. The company serves a diverse clientele, including pharmaceutical companies and research institutions engaged in life sciences innovation.Escalier Biosciences B.V. generates revenue through partnerships and collaborations in the biotechnology sector. Revenue streams are primarily driven by project-based funding and grants that support their research initiatives, reflecting the company's engagement with various organizations and stakeholders in the life sciences industry.Escalier Biosciences B.V. plans to launch new products focusing on innovative therapies and diagnostics aimed at improving patient outcomes. The company is targeting expansion into European and North American markets by the end of 2024. The recent funding of USD 19.00 mn from the Series B round will be utilized to enhance research capabilities and accelerate the development of new solutions, as well as support their entry into these new geographic regions.

## Funding rounds

- Series B, Mar 13, 2018, $19M — Forbion, BioGeneration Ventures, New Science Ventures
- Series A, Mar 20, 2017 — New Science Ventures

## Investors

- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series B